Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?

Bibiana Bielekova1, Michael P McDermott2

  • 1From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY. bibi.bielekova@nih.gov.

Neurology
|March 27, 2015
PubMed
Summary

No abstract available in PubMed .